ArticleTranslational cancer research2020
Decreased expression of farnesoid X receptor may indicate poor prognosis in patients with colorectal cancer.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Understanding microbiota-driven oncogenesis: The role of metabolites in tumorigenesis.iScience · 2025Review
- Emerging role of bile acids in colorectal liver metastasis: From molecular mechanism to clinical significance (Review).International journal of oncology · 2025Review
- Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling.Cellular oncology (Dordrecht, Netherlands) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the most common malignancies worldwide. Many studies showed that increased secretion of bile acid may contribute to the pathogenesis of CRC. Farnesoid X receptor (FXR) plays an important role in several physiological functions of bile acid metabolism and circulation, while the diagnostic and prognostic values of FXR remain unknown.
methodsWe used immunohistochemistry (IHC) to examine FXR expression in 132 formalin-fixed paraffin-embedded (FFPE) CRC samples, and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was also conducted to compare the mRNA expression of FXR between 50 fresh CRC tissues and 50 adjacent normal tissues. Immunohistochemical method has been used to compare the protein expression of FXR in FFPE samples, and the associate between FXR expression and clinical characteristics of the patients were also analyzed. Moreover, RT-qPCR has been applied to quantify the mRNA expression of FXR, and the diagnostic value and prognostic value of FXR were analyzed by receiver operating characteristics (ROC) analysis and Kaplan-Meier survival analysis, respectively.
resultsThe expression of FXR was significantly decreased in CRC tumor samples compared with normal tissues on both protein and mRNA levels, and the expression of FXR was positively correlated with the tumor size, lymph node metathesis and distant metathesis of the patients. Moreover, the area under curve (AUC) of FXR for the diagnosis of CRC was 0.8088, and low expression of FXR was associated with low overall survival (OS) and disease-free survival (DFS) rate.
conclusionsFXR was down-regulated in CRC and may serve as potential diagnostic and prognostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.